Following the publication of GlaxoSmithKline’s Q1 2019 results, which showed sales of its zoster virus vaccine Shingrix grew stronger than expected, even following remarkable sales in 2018,
James Mather, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on Shingrix’s future revenue potential:
“Even before approval, analysts anticipated Shingrix would be a reliable revenue stream for GSK and it has not disappointed with sales of the herpes zoster vaccine reaching $1bn in sales just over a year after its launch in late 2017.
“GSK’s Q1 earnings showed that the momentum in sales growth for the vaccine is not slowing; with GlobalData now forecasting that Shingrix sales will reach approximately $1,750M in 2019 before surpassing $2bn in 2020.”
“The Alum adjuvanted herpes zoster vaccine, Shingrix, was always expected to reach blockbuster status, after receiving a preferential recommendation from the CDC’s Advisory Committee on Immunization Practices over Merck’s Zostavax.
“Currently GSK are reaping the benefits of a strong marketing campaign targeting previously under-vaccinated elderly people against shingles, with sales of Shingrix expected to peak at approximately $2.5bn in the next 5 years.”